On Oct. 20, 2020, the NIH announced that the researchers had completed the Adaptive COVID-19 Treatment Trial (ACTT-1), funded by NIAID. The final report appeared in the New England Journal of Medicine on Oct. 8, 2020.

The final results showed that the antiviral treatment was beneficial, consistent with the preliminary findings. Patients who received remdesivir were quicker to recover, which was defined as being medically stable enough to be discharged from the hospital. The median recovery time was 10 days with remdesivir compared to 15 days for the placebo group.